New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2013
07:33 EDTMKGAY, OPXAOpexa Therapeutics, Merck Serono enter into license agreement for Tcelna
Opexa Therapeutics (OPXA) announced the execution of an agreement with Merck Serono, a division of Merck (MKGAY) for the development and commercialization of Tcelna, a potential first-in-class personalized T-cell therapy for patients suffering from multiple sclerosis. Tcelna is being developed by Opexa and currently is in a Phase IIb clinical trial in patients with Secondary Progressive MS. Potential payments to Opexa from the option and license agreement could total $225M based upon the successful development and commercialization of Tcelna for MS. Under the terms of the agreement, Opexa will receive an upfront payment of $5M for granting an option to Merck Serono for the exclusive license of the Tcelna program for the treatment of MS. The option may be exercised prior to or upon completion of Opexa’s ongoing Phase IIb clinical trial in patients with SPMS. Upon exercising this licensing option, Merck Serono would pay an upfront license fee of either $25M or $15M, and in return receive worldwide development and commercial rights to Tcelna in MS, excluding Japan. Additional financial considerations of the agreement include development and commercial milestone payments to Opexa of up to $195M and a tiered royalty rate from the high single digits to the mid-teens based on net sales payable to Opexa.
News For OPXA;MKGAY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
08:10 EDTOPXAOpexa Therapeutics to present biomarker data from NMO patients at AAN meeting
Opexa Therapeutics announced that it has been invited to present data on the immune profile of patients with NMO at the 67th American Academy of Neurology Annual Meeting in Washington D.C. Opexa will present the results of a study conducted to characterize the cellular immune profile of NMO patients prescribed B-cell depleting therapy in comparison to those of healthy donors. The results showed that despite administration of B-cell depleting therapy, inflammation continued to persist as did the presence of activated T-cells. Opexa has a preclinical development program in NMO and IND enabling activities are currently being conducted with its drug development candidate, OPX-212.
08:02 EDTMKGAYMerck KGaA, Pfizer initiate Phase III study with Avelumab
Subscribe for More Information
April 16, 2015
16:15 EDTOPXAFrigate Ventures reports 9.9% passive stake in Opexa Therapeutics
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use